China Clinical Trials Glossary (A–Z): Essential Terms, China Context, and Official References

Introduction

Running clinical trials in China requires fluency in terms that blend international standards (ICH, WHO) with China-specific policies, agencies, and operating practices. This A–Z glossary provides concise definitions, short “China context” notes, and links to authoritative sources that open in a new tab. Entries explicitly unique to the China environment are marked as China-Specific Term.

Table of Contents

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

A

Adaptive Design

Prospective trial design enabling pre-planned modifications based on interim data. China context: Accepted in NMPA submissions when statistical integrity is preserved and adaptations are pre-specified. (Reference: ICH E9)

Administrative License China-Specific Term

Formal permission issued under Chinese administrative law to perform regulated activities (e.g., drug import permit). China context: Required for many trial supply actions. (Reference: NMPA)

Assent (Child)

Affirmative agreement by a minor to participate, in addition to parental consent. China context: Ethics committees expect age-appropriate materials; cultural family decision-making should not override autonomy. (Reference: ICH E11)

Audit Trail

Secure, time-stamped record of data creation and changes. China context: Inspectors emphasize robust audit trails in EDC/LIMS and source systems. (Reference: ICH E6(R2))

Authorization Letter for IMP Customs China-Specific Term

Letter validating the entity authorized to handle import/export of investigational products. China context: Often required alongside permits and invoices at customs. (Reference: NMPA)

B

Batch Release (Clinical)

QA authorization for an IMP batch to be used in a trial. China context: Local QA/QP sign-off and retention samples often expected; documentation in Mandarin. (Reference: NMPA GMP)

BCS-Based Biowaiver

Waiver of in vivo BE studies for eligible BCS Class I/III drugs. China context: Considered under NMPA with strict dissolution and formulation sameness criteria. (Reference: ICH M9)

BE (Bioequivalence) Study

PK comparison of test and reference products within pre-specified limits. China context: Core to the 2016 generics quality consistency evaluation policy. (Reference: NMPA BE Guidance)

Biologics License Application (BLA)

Marketing application for biologics. China context: Submitted to CDE/NMPA with CMC, clinical, and PV systems evidence; may access priority pathways. (Reference: CDE/NMPA)

Bridging Study

Study to extrapolate foreign data to Chinese population. China context: Still used, but MRCT under ICH E17 increasingly reduces bridging needs. (Reference: ICH E5)

C

CAPA

Corrective and preventive actions addressing root causes of nonconformities. China context: Central to inspection responses and ongoing site/CRO quality improvements. (Reference: ICH Q10)

CCDRS / CDE China-Specific Term

Center for Drug Evaluation, NMPA’s technical review body. China context: Reviews IND/NDA/BLA and issues technical opinions. (Reference: CDE (China))

CDISC Standards

Global data standards (SDTM, ADaM) for submissions. China context: Increasingly requested to facilitate multinational data integration. (Reference: CDISC)

Clinical Trial Institution Filing System China-Specific Term

Reform enabling hospitals to file GCP readiness and conduct trials after approval. China context: Replaced older site-by-site approvals in 2019. (Reference: NMPA)

Combined Drug–Device Trial

Study of products integrating drug and device components. China context: Requires coordination between drug and device review pathways. (Reference: NMPA)

Conditional Approval China-Specific Term

Provisional marketing authorization based on early efficacy for serious conditions; requires confirmatory studies. (Reference: NMPA Conditional Approval)

Consistency Evaluation of Generics (2016) China-Specific Term

Policy mandating quality/efficacy alignment of generics with reference drugs, centered on BE studies. (Reference: NMPA Policy)

CRC (Clinical Research Coordinator)

Site-based role coordinating daily trial operations. China context: Ubiquitous in Tier-1/Tier-2 hospitals; training records heavily scrutinized. (Reference: WHO GCP)

CRO (Contract Research Organization)

External provider for monitoring, data, PV, etc. China context: Hybrid global–local models are common to balance quality and recruitment agility. (Reference: ICH E6(R2))

D

Data Localization China-Specific Term

Requirement to store/process personal information and certain research data within China; cross-border transfers subject to review. (Reference: CAC (China))

Data Monitoring Committee (DMC/DSMB)

Independent oversight of safety/efficacy interim data. China context: Charter and membership independence evaluated by ethics committees. (Reference: WHO GCP)

Development Safety Update Report (DSUR)

Annual cumulative safety report for investigational products. China context: Alignment with ICH E2F; timelines coordinated with IND renewals. (Reference: ICH E2F)

Drug Administration Law (2019) China-Specific Term

Modernized legal foundation for drug regulation, inspections, and penalties. (Reference: NMPA)

E

EC (Ethics Committee)

Independent body safeguarding participant rights and welfare. China context: EC filing, SOPs, and minutes are frequent inspection targets. (Reference: ICH E6(R2))

eConsent

Electronic informed consent using multimedia and e-signatures. China context: Increasingly accepted, with validation and audit trail expectations; rural deployment may require offline capability. (Reference: NMPA)

eCTD

Electronic Common Technical Document format for submissions. China context: CDE portals support eCTD for IND/NDA/BLA. (Reference: ICH M4)

Emergency Use in Trials

Protocol-defined emergency measures to protect subjects. China context: COVID-era policies enabled continuity with documentation of deviations. (Reference: WHO GCP)

F

Fast-Track / Priority Review China-Specific Term

Expedited NMPA review for urgent public health needs or significant clinical value. (Reference: NMPA Priority Channels)

Feasibility Assessment

Evaluation of sites, investigators, and patient pools. China context: Includes EC capacity, prior NMPA inspection history, and bilingual capability. (Reference: WHO GCP)

FIH (First-in-Human)

Initial exposure of humans to a new drug. China context: Requires robust preclinical/HGRAC (if genetics) and risk mitigation plans. (Reference: ICH M3(R2))

G

GCP (Good Clinical Practice)

International standard for ethical and scientific trial conduct. China context: NMPA aligns with ICH E6(R2) and inspects for compliance. (Reference: ICH E6(R2))

GMP / GSP

Manufacturing and supply standards for IMPs. China context: Local certificates, Mandarin labels, and controlled distribution are expected. (Reference: NMPA GMP/GSP)

Green Channel for Vaccines China-Specific Term

Priority mechanisms to expedite critical vaccine trials/approvals. (Reference: NMPA Vaccines)

H

Hainan Boao Lecheng RWD Pilots China-Specific Term

Pilot zone allowing use of imported medical devices/drugs and generation of real-world data to support approvals. (Reference: Hainan FTZ)

HGRAC (Human Genetic Resources Administration of China) China-Specific Term

Authority overseeing collection, use, and export of human genetic resources in research. (Reference: MOST / HGRAC)

Hybrid Decentralized Trial

Combination of site visits and remote procedures. China context: Requires validation of remote tools and data privacy compliance (PIPL/CAC). (Reference: WHO Guidance)

I

IB (Investigator Brochure)

Compiled preclinical/clinical data supporting the investigational product’s use in humans. (Reference: ICH E6(R2))

ICF (Informed Consent Form)

Participant document describing purpose, risks, and rights. China context: Mandarin language; dialect translations considered in rural settings. (Reference: ICH E6(R2))

ICH E17 MRCT

Guideline for multi-regional clinical trials to enable global data pooling. China context: Adopted by NMPA; strengthens inclusion of Chinese data without bridging. (Reference: ICH E17)

Import Drug License / Trial Import Permit China-Specific Term

Authorization for importing IMPs/comparators for clinical use. (Reference: NMPA)

IND (Investigational New Drug)

Application to start clinical trials. China context: 60-day “silent approval” if no objections. (Reference: CDE/NMPA)

Inspection (NMPA GCP) China-Specific Term

Regulatory audits of sites/sponsors/CROs focusing on consent, TMF, SDV, and PV. (Reference: NMPA GCP)

J

Just-In-Time Site Activation

Operational approach to open sites close to recruitment need. China context: Must align with institution filing status and EC throughput. (Reference: WHO GCP)

K

Key Risk Indicators (KRIs)

RBM metrics to detect emerging quality risks across sites. China context: Useful when monitoring Tier-2 sites ramping up trial capacity. (Reference: FDA RBM Guidance)

L

Labeling (Mandarin Clinical Label) China-Specific Term

Mandarin labels on IMPs must include protocol, batch, storage, and “For Clinical Trial Use Only.” (Reference: NMPA IMP Labeling)

Local Comparator Sourcing China-Specific Term

Acquisition of reference drugs approved in China for active-controlled trials/BE. (Reference: CDE/NMPA)

M

Medical Device Clinical Trial Filing China-Specific Term

Device trials follow device-specific filings/approvals distinct from drug IND. (Reference: NMPA Medical Devices)

MRCT (Multi-Regional Clinical Trial)

Global study recruiting across multiple regions. China context: E17 implementation boosts Chinese cohort acceptance. (Reference: ICH E17)

Most-Favored Review Pathways China-Specific Term

Breakthrough/priority/conditional channels for high-value therapies. (Reference: NMPA Fast Channels)

N

NDA/BLA (Marketing Application)

Comprehensive dossier for market authorization. China context: Parallel CMC, GCP, GMP inspections may occur. (Reference: CDE)

NMPA (National Medical Products Administration) China-Specific Term

Central authority for drug/device regulation and clinical trials. (Reference: NMPA)

NRDL Evidence Package China-Specific Term

Real-world and economic evidence supporting inclusion in the National Reimbursement Drug List post-approval. (Reference: NHSA (China))

O

Observational Registry (China) China-Specific Term

Hospital/center-based registry used for RWD/RWE; privacy and HGRAC implications if genetic data involved. (Reference: NMPA RWE)

Orphan / Rare Disease Pathway China-Specific Term

Policies to expedite rare disease trials and approvals via priority channels and guidance. (Reference: NMPA)

P

Patient-Reported Outcomes (PRO)

Outcomes reported directly by patients. China context: Translations/linguistic validation for Mandarin and dialects required. (Reference: FDA PRO Guidance)

Pediatrics Ethical Safeguards (China) China-Specific Term

Heightened consent/assent and safety monitoring in pediatric trials; ECs emphasize risk minimization. (Reference: ICH E11)

PIPL (Personal Information Protection Law) China-Specific Term

Comprehensive data privacy law governing processing/transfer of personal data in trials. (Reference: NPC (China))

Priority Review / Breakthrough Therapy China-Specific Term

Accelerated review/designation for significant clinical value; may shorten NDA/BLA timelines. (Reference: NMPA Priority)

Protocol in Mandarin China-Specific Term

Bilingual protocols (Chinese–English) often required for EC review/site conduct; certified translations recommended. (Reference: NMPA GCP)

Q

QP-Equivalent for Clinical Batch Release China-Specific Term

Designated quality person in China who authorizes clinical batch release per local GMP/GSP. (Reference: NMPA GMP)

Quality Consistency Evaluation (Generics) China-Specific Term

See “Consistency Evaluation of Generics (2016).” Core driver of China’s BE ecosystem. (Reference: Policy)

R

RBM (Risk-Based Monitoring)

Monitoring focused on critical data/processes and emerging risk signals. China context: Useful for geographically dispersed Tier-2 networks. (Reference: FDA RBM)

Real-World Evidence (RWE) China-Specific Term

Use of RWD to support regulatory decisions; NMPA issued guidance and pilots (e.g., Hainan). (Reference: NMPA RWE)

Registration Classification (China) China-Specific Term

Category system defining new drugs, improved generics, biosimilars, etc., guiding data requirements. (Reference: CDE)

S

SAE/SUSAR Reporting (China Timelines) China-Specific Term

Expedited safety reporting requirements to CDE/ECs per China GCP and ICH E2A alignment. (Reference: ICH E2A)

Silent Approval (60-Day Rule) China-Specific Term

Trials may start 60 days after IND acceptance if no CDE objection is issued. (Reference: CDE)

Site File (China) China-Specific Term

Investigator Site File with Mandarin documents, EC approvals, and training certificates inspected for completeness. (Reference: NMPA GCP)

Special Review for Urgent Clinical Need China-Specific Term

Expedited pathway for drugs addressing urgent clinical needs in China. (Reference: CDE/NMPA)

Sub-Center EC Oversight China-Specific Term

Large hospitals with branch centers ensure EC governance across multiple departments/branches. (Reference: GCP)

T

TCM (Traditional Chinese Medicine) Trial Endpoints China-Specific Term

Hybrid endpoints mixing biomedical measures with TCM syndrome differentiation. (Reference: NMPA TCM)

Tier-1 vs Tier-2 Hospitals China-Specific Term

Informal shorthand: Tier-1 = top academic/tertiary; Tier-2 = regional/secondary. Implications for capacity, QA, and training. (Reference: NHC (China))

TMF (Trial Master File)

Collection of essential documents demonstrating compliance. China context: Bilingual TMFs common for MRCTs; rigorous EC correspondence. (Reference: ICH E6(R2))

Translational Sample Export Controls China-Specific Term

Export of human biospecimens often requires HGRAC approval and customs permits. (Reference: HGRAC/MOST)

U

Unannounced Inspection (China) China-Specific Term

Risk-based NMPA inspections without prior notice to assess real-time compliance. (Reference: GCP Inspection)

UDCA (Urgent Data Cleaning Actions)

Time-sensitive data quality corrections near database lock. China context: Sponsor/CRO escalation pathways expected. (Reference: CDISC)

V

Vaccine Clinical Trial Registration (China) China-Specific Term

Registration, protocol review, and batch testing under vaccine-specific regulations. (Reference: NMPA Vaccines)

Virtual Site Visit / Remote Monitoring

Monitoring visit conducted remotely using validated systems. China context: Documentation of limitations and privacy controls required. (Reference: FDA RBM)

W

Waiver of In-Country Comparator China-Specific Term

Justification to use non-China approved comparator when local source is unavailable; requires strong rationale. (Reference: CDE)

WHO-GCP

Global ethical and scientific quality standard. China context: Referenced with ICH and local GCP during inspections and training. (Reference: WHO GCP)

X

X-Clinical Data Warehouse (Hospital) China-Specific Term

Hospital-specific integrated data lakes used for feasibility/RWD; access governed by local privacy rules and EC oversight. (Reference: NHC)

Y

Yearly EC Continuing Review

Annual review of ongoing studies by ethics committees. China context: Many ECs require progress reports and any protocol modifications in Mandarin. (Reference: ICH E6(R2))

Z

Zero-Tolerance for Data Fabrication China-Specific Term

NMPA enforcement priority; significant penalties and listing of violators; strong deterrent for GCP breaches. (Reference: NMPA Enforcement)

Additional High-Value Terms (A–Z Supplement)

Adverse Event Terminology (MedDRA in China)

Standard coding of AEs using MedDRA; bilingual coding practices may apply. (Reference: MedDRA)

Archiving Period (China) China-Specific Term

Retention timelines for essential documents per China GCP/local laws, often longer for pediatric/biologic trials. (Reference: GCP)

Back-Translation (Regulatory)

Independent translation back to the source language to validate accuracy of Mandarin trial documents. (Reference: ICH E6(R2))

Biomarker-Companion Diagnostic Co-Development

Parallel drug–diagnostic development and validation. China context: Requires NMPA alignment on both streams; lab accreditation critical. (Reference: NMPA IVD)

Case Report Form (Bilingual) China-Specific Term

CRFs available in Chinese and English to minimize translation errors and speed global data integration. (Reference: CDISC)

Central Lab Network (China)

Accredited labs providing standardized testing; logistics and sample chain-of-custody are inspection points. (Reference: CNCA (China))

Clinical Pharmacology Unit Accreditation China-Specific Term

Accreditation required for BE/PK studies; inspected for sample handling and bioanalysis. (Reference: CDE)

Comparator Import Waiver China-Specific Term

Allowance to use overseas comparators with documentation if local sourcing infeasible. (Reference: CDE)

Data Privacy Impact Assessment (DPIA)

Assessment of privacy risks for trial data flows. China context: Often required under PIPL and CAC rules for cross-border transfers. (Reference: CAC)

Decentralized Procedures (Home Health / Telemedicine)

Remote visits and procedures to reduce site burden; validation and training documented for inspections. (Reference: WHO)

EC Reciprocal Review (Multi-Center) China-Specific Term

Use of leading site EC approval to streamline multi-center startup where permitted. (Reference: NHC)

Electronic Source (eSource)

Direct capture of source data electronically; audit trail and system validation required. (Reference: ICH E6(R2))

Essential Documents (Mandarin Index) China-Specific Term

TMF/ISF indices in Mandarin to support NMPA inspections and staff turnover. (Reference: GCP)

Export Permit for Human Biospecimens China-Specific Term

Permit needed for sample export; requires HGRAC and customs documentation. (Reference: HGRAC)

Foreign Sponsor Local Agent China-Specific Term

Designated local entity responsible for communications with CDE/NMPA and compliance. (Reference: NMPA)

GxP Inspection Integration

Coordination of GCP/GMP/GDP inspections tied to NDA/BLA. China context: Sponsors plan inspection readiness across streams. (Reference: NMPA)

Hospital Research Office (IRO) China-Specific Term

Institutional unit coordinating contracts, budgets, EC submissions, and site capacity. (Reference: NHC)

Import VAT/Customs for IMP China-Specific Term

Taxation and customs processes applicable to clinical supplies; documentation accuracy critical to avoid delays. (Reference: China Customs)

In-Country Calibration (Devices/Diagnostics) China-Specific Term

Requirement that certain diagnostic platforms be calibrated by certified local entities. (Reference: Devices/IVD)

Language Validation (Patient Materials)

Linguistic validation and readability testing for ICF/PROs in Mandarin and dialects. (Reference: FDA PRO)

Local Cold-Chain Qualification China-Specific Term

Qualification of refrigerators, shippers, and depots per local standards; temperature logs audited. (Reference: GSP)

Medical Insurance for Trial Participants (China) China-Specific Term

Insurance requirements and coverage disclosures in ICFs; varies by region/hospital policy. (Reference: GCP/Local)

Negative-List Drugs (Import Controls) China-Specific Term

Categories subject to enhanced import scrutiny; affects trial supply strategies. (Reference: Customs)

Packing Configuration in Mandarin China-Specific Term

Cartons/inserts labeled in Mandarin; master labels and QP release docs retained in TMF. (Reference: IMP Labeling)

Pharmacovigilance System Master File (PSMF-CN) China-Specific Term

Local PV master file describing safety system in China. (Reference: PV Guidance)

Principal Investigator Qualification File China-Specific Term

Mandarin CV/license/training package kept current for inspections. (Reference: GCP)

Project Filing with Hospital Finance China-Specific Term

Budget/contract filing managed by the hospital’s finance/research office before SIV. (Reference: NHC)

QR-Coded IMP Tracking China-Specific Term

Use of QR codes in local supply systems for chain-of-custody; logs inspected by NMPA. (Reference: GSP)

Rare Disease Mapping to National Catalog China-Specific Term

Alignment with China’s rare disease catalog supports expedited pathways and reimbursement dialogues. (Reference: NHC)

Readiness Checklist (China SIV) China-Specific Term

Mandarin binder including EC approvals, delegation log, equipment calibration, and emergency procedures. (Reference: GCP)

Regulatory-Compliant Translation Certificate

Translator attestation added to key documents for EC/CDE acceptance. (Reference: ICH E6(R2))

Serology/Virology Local Testing Certification China-Specific Term

Local lab certifications required for infectious disease testing used as endpoints/safety. (Reference: CNCA)

Site Nurse Coordinator Model China-Specific Term

Dedicated research nurses supporting CRC/PI in high-volume hospitals; training logs audited. (Reference: NHC)

Source Data (Chinese Medical Records) China-Specific Term

Hospital charts in Chinese; certified translations/back-translations for global regulators may be requested. (Reference: ICH E6(R2))

Statistical Subgroup justification (China Cohort) China-Specific Term

E17-aligned rationale for Chinese sample size and pooling strategy. (Reference: ICH E17)

Traditional Medicine Quality Monograph China-Specific Term

Standardized specs for TCM raw materials/formulations; heavy metal/pesticide tests required. (Reference: TCM/Pharmacopeia)

Trial Insurance Certificate (China) China-Specific Term

Proof of participant coverage; often appended to ICF and contract package. (Reference: GCP)

UD/UR (Urgent Protocol Deviation/Report)

Immediate deviations to protect subjects reported to EC/CDE per local timelines. (Reference: ICH E6(R2))

Vaccination Record Integration (China EHR) China-Specific Term

Integration with local EHR registries for eligibility/safety checks in vaccine trials. (Reference: NHC)

Wearable Device Validation (Local) China-Specific Term

Demonstration that digital endpoints from wearables meet China privacy and performance standards. (Reference: CAC)

eTMF Access Controls (China) China-Specific Term

Role-based access and server location policies documented for inspections; cross-border access logged. (Reference: CAC/PIPL)

Note: This glossary contains more than 100 entries. All China-specific elements are marked and paired with links to official or primary sources that open in new tabs.

Conclusion & Call-to-Action

China’s clinical trial landscape blends international best practices with distinctive national frameworks. Use this glossary as a working reference to decode regulatory pathways, prepare inspection-ready documentation, and design China-inclusive protocols under ICH E17. For program-level planning, map your terminology and document set to NMPA expectations, HGRAC requirements (for genetics), and data privacy prerequisites under PIPL/CAC. Align early with CDE on design choices, bilingual documentation, and MRCT pooling strategies to ensure global acceptability of Chinese data.